By Topic
.webp&w=828&q=75)
Austral Resources Australia (ASX: AR1): Stock Tests Resistance with Copper Growth in Focus
Austral Resources is drawing fresh attention through its Rocklands restart plans, Hammer Metals acquisition, copper exploration results, and infrastructure investment, while AR1’s chart approaches an important resistance zone with speculative risks still in focus.
.webp&w=828&q=75)
Locksley Resources (ASX: LKY): Mojave Exploration Halt Hits Sentiment as Sellers Retake Control
Locksley Resources faces investor pressure after pausing Mojave exploration activities. The company is reassessing project spending, focusing on preserving assets, and reviewing future opportunities across its critical minerals portfolio.
.webp&w=828&q=75)
Tribune Resources (ASX: TBR): Operational Discipline and Strategic Leverage in Gold Production
Tribune Resources (ASX: TBR) demonstrates disciplined operations and resilient cash generation through its East Kundana Joint Venture (EKJV) with Evolution Mining, maintaining strong production and resource confidence amid cost pressures and market volatility.
.webp&w=828&q=75)
Meteoric Resources (ASX: MEI): Low-Cost Mining, Billion-Dollar DFS, and a Path to Production
Meteoric Resources (ASX: MEI) delivers a robust DFS for its Caldeira Rare Earth Project, confirming Tier‑1 scale, low‑cost production, and strategic positioning in global rare‑earth supply chains.
Carnegie Clean Energy (ASX: CCE): Operational Milestone Tests Whether CCE Can Break Its Downtrend
Carnegie Clean Energy (ASX: CCE) is advancing CETO wave-energy deployment and MoorPower commercialisation, supported by grants and $2.5 million placement. While October’s Spain deployment could be a catalyst, CCE remains a volatile, pre-commercial stock facing execution, funding and dilution risks.
Mesoblast (ASX: MSB): Shares Declined Despite Ryoncil Momentum as Investors Lock In Profits
Mesoblast (ASX: MSB) is transitioning into a commercial-stage biotech as Ryoncil® sales accelerate and its late-stage pipeline advances. While the share price has eased after a strong rally, growing revenue, improving cash flow, and multiple clinical catalysts continue to support its long-term outlook.
...